menu
    • menu
    [{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVZO-021","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Allorion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"VelaVigo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Duality Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":1.2,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Allorion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"AVZO-023","moa":"CDK4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Avenzo Therapeutics

    Menu

    Avenzo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-1418

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avenzo gets IND Clearance for AVZO-1418 EGFR/HER3 Bispecific ADC

                            Details : AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate. It is being evaluated for the treatment of advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 22, 2025

                            Lead Product(s) : AVZO-1418

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-023

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Allorion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avenzo gets FDA IND Clearance for AVZO-023 CDK4 Inhibitor for Cancer

                            Details : Under the licensing agreement, Avenzo has exercised its exclusive option for global (excluding Greater China) development, manufacturing, and commercialization rights for AVZO-023.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 21, 2025

                            Lead Product(s) : AVZO-023

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Allorion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1418

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Duality Biologics

                            Deal Size : $1,200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avenzo, DualityBio Sign License for EGFR/HER3 Antibody-Drug Conjugate

                            Details : Under the licensing agreement, Venzo will develop, manufacture and commercialize AVZO-1418 (DB-1418), a potential best-in-class bispecific ADC for treating neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $50.0 million

                            January 07, 2025

                            Lead Product(s) : DB-1418

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Duality Biologics

                            Deal Size : $1,200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : VelaVigo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            VelaVigo Licenses Nectin4/TROP2 Bispecific Antibody-Drug Conjugate from Avenzo

                            Details : Avenzo gains an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : VelaVigo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-021,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Allorion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avenzo Announces Global License of AVZO-021 (ARTS-021) from Allorion Therapeutics

                            Details : Under the agreement, Avenzo will develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 selective inhibitor globally, excluding Greater China.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : AVZO-021,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Allorion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : New Enterprise Associates

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Avenzo Therapeutics Announces $150M Oversubscribed Financing for Oncology

                            Details : Proceeds will advance Avenzo’s ARTS-021, a selective CDK2 inhibitor in a Phase 1 study for HR+/HER2- metastatic breast cancer and other advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : New Enterprise Associates

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-021,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Avenzo Partners with Gilead For Breast Cancer Study with AVZO-021

                            Details : The collaboration aims to evaluate AVZO-021, a best-in-class CDK2 inhibitor, in combination with Gilead’s Trodelvy (sacituzumab govitecan), for patients with HR-positive, HER2-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 09, 2024

                            Lead Product(s) : AVZO-021,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-021

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of AVZO-021 in Patients With Advanced Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 19, 2023

                            Lead Product(s) : AVZO-021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth